Our study suggests that clinicopathological factors, including primary tumor characteristics, stage of metastatic disease, and serum LDH and S100B, can be used in the prognostic stratification of metastatic melanoma patients treated with BRAF and MEK inhibitors. Here, BRAF is linked to metastatic melanoma.